Figure 6.
METTL3 promoted tumor growth in vivo. (A) Representative images of subcutaneous HeLa tumors growth in xenografted BALB/c nude mice. Each group of mice was ectopically implanted with 5 × 106 indicated cells into the flanks of mice (n > 9). Here, cells were transfected with shRNA (shNC or shMETTL3) or overexpression (oeNC or oeMETTL3) lentiviral vector. (B) Tumors were harvested 22 days after cell injection, and the weights of the tumors that formed in the subcutaneously implanted mouse model were measured. The data are presented as the mean ± SEM tumor weight, * P < 0.05, **** P < 0.0001(one-way ANOVA analysis) for the indicated comparisons. (C) The size of the tumors that formed in the subcutaneously implanted mouse model was monitored every 2 days. The data are presented as the mean ± SEM tumor volume, ** P < 0.01, *** P < 0.001(one-tailed t-test) for the indicated comparisons. (D) Western blotting assay of METTL3 and CDC25B protein expression in the tumors from each group. Data are representative of 3 different tumors from each group. GAPDH served as a loading control. (E) Immunohistochemical staining of the METTL3 and CDC25B protein in human cervical tumors (n=39). (Magnification: 100× and 400×). IHC images of patients 1 to 3 were selected to show collaborative high expression of METTL3 and CDC25B, whereas images of patient 4 displayed low expression of these proteins. (F) Heatmap displayed the IHC scores of METTL3 and CDC25B in 39 human cervical tumor samples. (G) The Number of tumors expressing high (H) or low (L) levels of CDC25B in tumors with high (H) or low (L) METTL3 expression. *** P < 0.001 (Student's t-test)